
Sign up to save your podcasts
Or


Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment.
Read the trials:
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00213-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninf
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00289-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninf
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet GroupLilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment.
Read the trials:
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00213-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninf
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00289-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninf
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

7,625 Listeners

880 Listeners

140 Listeners

325 Listeners

497 Listeners

130 Listeners

3,369 Listeners

112,611 Listeners

56,603 Listeners

93 Listeners

368 Listeners

21 Listeners

0 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

2 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

32 Listeners

83 Listeners

3 Listeners

0 Listeners

5 Listeners

0 Listeners

0 Listeners

0 Listeners